$HIMS

Hims & Hers Health (HIMS) faces a securities class action lawsuit following an FTC complaint alleging misconduct, including improper sharing of health data and deceptive billing practices. The FTC's lawsuit caused HIMS shares to drop 14.7% on July 29, 2026, erasing $970M in market cap. The lawsuit claims HIMS misled investors about its business practices and internal controls.

Hims & Hers Health (HIMS) reports strong momentum from weight-loss offerings, international expansion, and AI-enabled care, with Q2 revenues up 40% YoY. However, gross-margin pressure and regulatory uncertainty pose challenges. Shares gained 3.4% in 3 months, outperforming the S&P 500. Earnings are estimated to improve 19.5% over 5 years.

Novo Nordisk (NVO) shares rose 3.6% after Hims & Hers withdrew its discounted GLP-1 pill, easing competition. Novo Nordisk's Wegovy pill gained access to Hims & Hers patients. The FDA supports branded GLP-1 drugs. Novo Nordisk raised 2026 guidance in August, citing strong Wegovy adoption.

Hims & Hers Health (HIMS) stock fell 4% to $28.44 on Tuesday after the FDA issued a warning about unapproved GLP-1 weight-loss drugs. The company expanded into Australia but faces profitability pressures due to higher costs of approved GLP-1s. HIMS reported $753M revenue and an $86M net loss in Q2, raising its 2026 revenue forecast to $3.1B-$3.3B.

Wall Street's major indexes closed lower as oil prices topped $95 and Treasury yields climbed, sparking a risk-off mood. The Dow, S&P 500, and Nasdaq fell 0.8%, 0.7%, and 1% respectively. Higher oil prices and yields raised inflation and borrowing cost concerns. Several companies, including Apple, reported earnings or leadership changes.

Hims & Hers Health (HIMS) expanded into Australia, its first Asia-Pacific market, via the acquisition of Eucalyptus. The company launched weight-loss and men's health treatments, with women's health services planned. The move aims to replicate its U.S. and European model, leveraging local infrastructure. International expansion has increased monthly revenue per subscriber by 21% year over year, but has also pressured gross margins.

Hims & Hers Health Inc (HIMS) launched GLP-1 weight-loss drugs and other treatments in Australia via its Pilot platform. The company acquired Eucalyptus, an Australian digital health platform, earlier in 2026. Hims aims to expand its services and targets $6.5 billion in revenue by 2030, though international growth has impacted gross margins. According to the company, international business has increased subscriptions and monthly revenue per subscriber by 21% year-over-year.

U.S. stock futures rose after President Trump stated the U.S.-Iran war is 'very close to over.' The S&P 500 and Nasdaq Composite closed at record highs. HIMS surged 24% on FDA news, MSFT gained on AI sentiment, RUM hit a month high, NFLX rose ahead of earnings, and XNDU had its best day. Oil steadied near $91/barrel.

Hims & Hers (HIMS) CEO Andrew Dudum defended the company against an FTC lawsuit, citing its revenue growth and subscriber base. Q2 revenue rose 40% YoY to $753M, with a full-year forecast of $3.1B-$3.3B. However, margins fell to 64% from 76%, and free cash flow was negative $68M, raising concerns about profitability and legal risks.

U.S. stock futures were mixed on Tuesday, with Nasdaq and Russell 2000 futures up 0.1%, Dow futures down 0.1%, and S&P 500 futures flat. Investors await July CPI data and geopolitical tensions impact sentiment. Key earnings reports include SMCI, CRWV, CAVA, LITE, and SLS. NVDA labeled AI data centers as investable assets, INTC upsized its share sale to $20B, and RIOT secured a $9.1B deal. RKLB shares fell despite a revenue beat, ASTS extended selloff, and SPCX faced lockup expiration pressures.